Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > We're still...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(112)
•••
Comment by MBT123on Feb 18, 2021 10:58pm
256 Views
Post# 32606530

RE:RE:RE:RE:RE:We're still...

RE:RE:RE:RE:RE:We're still...Updates elsewhere on your .47 cent website..Was that in the GoDaddy bargain bin? Not one thing you have ever spewed not one has ever materialized into any share holder value which the quality of that sight reflects..But keep on researching its doing the company well. Every time someone blowing out shares you have always felt they "didn't" know and you felt bad..you been saying that for years. Not a single one regrets those now. Everyone keeps saying the company can make the SP a $1 too exercise warrants our part-time CEO going to become full-time? Or maybe if they "actually" had this billion dollar potential and cash in "some" deals they would Just let those 6million warrants expire..But I'm sure like the past 7years company will just kick that expiry down the road as well(JD will say good that is)Our part-time CEO must have really knocked it outta the park this week 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities